GLRA
CRMD icon

Gerald L. Ray & Associates’s CorMedix CRMD Stock Holding History

Gerald L. Ray & Associates’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$30K Sell
11,400
-14,000
-55% -$29K ﹤0.01% 327
2017
Q2 		$54K Sell
25,400
-6,400
-20% -$21.9K 0.01% 322
2017
Q1 		$259K Sell
31,800
-2,400
-7% -$22.9K 0.04% 281
2016
Q4 		$262K Sell
34,200
-1,400
-4% -$14.2K 0.04% 269
2016
Q3 		$449K Buy
35,600
+9,600
+37% +$89.7K 0.07% 211
2016
Q2 		$259K Sell
26,000
-2,100
-7% -$32K 0.04% 265
2016
Q1 		$372K Buy
28,100
+7,200
+34% +$69.9K 0.06% 210
2015
Q4 		$212K Sell
20,900
-4,940
-19% -$56.9K 0.03% 284
2015
Q3 		$257K Buy
25,840
+2,800
+12% +$43.2K 0.04% 251
2015
Q2 		$447K Buy
23,040
+19,120
+488% +$656K 0.07% 212
2015
Q1 		$193K Buy
3,920
+900
+30% +$21.3K 0.03% 302
2014
Q4 		$29K Sell
3,020
-200
-6% -$1.59K ﹤0.01% 299
2014
Q3 		$30K Hold
3,220
– – ﹤0.01% 298
2014
Q2 		$29K Buy
3,220
+950
+42% +$8.1K ﹤0.01% 302
2014
Q1 		$28K Buy
+2,270
New +$26.7K 0.01% 286

Other funds holding CRMD

EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bollard Group Boston, Massachusetts $3.29B AUM 4.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Gerald L. Ray & Associates's CRMD Position: Q3 2017 in Review

Gerald L. Ray & Associates reduced its CorMedix (CRMD) stake by 55% in Q3 2017, selling an estimated $29K and leaving 11,400 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #327.

Gerald L. Ray & Associates first reported a position in CRMD in Q1 2014 and has held it in 15 quarters since. The position peaked at $449K in Q3 2016. 33 funds tracked by Wall St. Rank hold CRMD as of Q3 2017.

  • Gerald L. Ray & Associates held 11,400 shares of CorMedix worth $30K as of Q3 2017.
  • Gerald L. Ray & Associates sold 14,000 CorMedix shares in Q3 2017, an estimated $29K.
  • CorMedix made up ﹤0.01% of Gerald L. Ray & Associates's portfolio in Q3 2017, its #327 holding.
  • Gerald L. Ray & Associates first reported a position in CorMedix in Q1 2014 and has held it in 15 quarters since.
  • Gerald L. Ray & Associates's CorMedix position peaked at $449K in Q3 2016.
  • 33 funds tracked by Wall St. Rank held CorMedix as of Q3 2017.

Based on Gerald L. Ray & Associates's 13F filing for Q3 2017, filed 31 Oct 2017.